Gilead Sciences (GILD)

61.40 -1.39 (2.21%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (4/30/21 *Est.)
- M&A (6/30/20 *Est)
- M&A (12/31/20 *Est)
- Conference (3/4/2021)

Latest Headlines

Form 10-K GILEAD SCIENCES INC For: Dec 31 February 25, 2021 4:18 PM - SEC Filing Gilead Sciences to Present at Upcoming Investor Conferences February 18, 2021 8:01 AM - BizWire Form SC 13G/A GILEAD SCIENCES INC Filed by: Capital Research Global Investors February 16, 2021 3:47 PM - SEC Filing Form SC 13G/A GILEAD SCIENCES INC Filed by: Capital Research Global Investors February 16, 2021 1:28 PM - SEC Filing Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach February 16, 2021 10:30 AM - BizWire Form 4 GILEAD SCIENCES INC For: Feb 10 Filed by: Wilfong Diane E. February 11, 2021 5:58 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Feb 10 Filed by: Pletcher Brett A February 11, 2021 5:56 PM - SEC Filing Gilead's (GILD) Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma February 10, 2021 5:15 PM - StreetInsider Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma February 10, 2021 5:15 PM - BizWire FibroGen (FGEN), Pliant Therapeutics (PLRX) to Benefit from Galapagos (GLPG)/Gilead (GILD) Discontinued ISABELA Phase 3 Trials in IPF - Citi February 10, 2021 3:57 PM - StreetInsider Form SC 13G/A GILEAD SCIENCES INC Filed by: VANGUARD GROUP INC February 10, 2021 10:59 AM - SEC Filing Galapagos (GLPG) and Gilead (GILD) Discontinue ISABELA Phase 3 Trials in IPF February 10, 2021 9:01 AM - StreetInsider Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF February 10, 2021 9:00 AM - BizWire Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF February 10, 2021 9:00 AM - StreetInsider Form 4 GILEAD SCIENCES INC For: Feb 06 Filed by: Wilfong Diane E. February 9, 2021 7:47 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Feb 06 Filed by: Pletcher Brett A February 9, 2021 7:44 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Feb 06 Filed by: Dickinson Andrew D February 9, 2021 7:41 PM - SEC Filing Kite Appoints Frank Neumann as Worldwide Head of Clinical Development February 8, 2021 8:00 AM - BizWire Gilead Sciences (GILD) PT Raised to $84 at Jefferies February 5, 2021 8:23 AM - StreetInsider Gilead Sciences (GILD) PT Raised to $67 at BMO Capital February 5, 2021 6:50 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $75 at Cowen February 5, 2021 6:41 AM - StreetInsider Gilead Sciences (GILD) PT Raised to $67 at Truist Securities February 5, 2021 6:40 AM - StreetInsider Gilead Sciences (GILD) PT Raised to $87 at Morgan Stanley on 4 Catalysts Driving 2021 Revenue Growth February 5, 2021 3:10 AM - StreetInsider Form 8-K GILEAD SCIENCES INC For: Feb 04 February 4, 2021 4:05 PM - SEC Filing Gilead Sciences (GILD) Raises Quarterly Dividend 4.4% to $0.71; 4.3% Yield February 4, 2021 4:03 PM - StreetInsider Gilead Sciences (GILD) Tops Q4 EPS by 4c, Offers FY Guidance February 4, 2021 4:03 PM - StreetInsider Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend February 4, 2021 4:02 PM - BizWire Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results February 4, 2021 4:01 PM - BizWire Gilead Sciences (GILD) call put ratio 3.5 calls to 1 put into quarter results and outlook February 4, 2021 10:24 AM - StreetInsider Ligand Pharma (LGND) PT Raised to $310 at H.C. Wainwright After Revenue Tops Expectations February 4, 2021 6:45 AM - StreetInsider Form 4 GILEAD SCIENCES INC For: Feb 01 Filed by: Pletcher Brett A February 3, 2021 6:24 PM - SEC Filing Gilead Sciences (GILD) weekly IV flat into quarter results and outlook February 3, 2021 10:17 AM - StreetInsider Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice February 2, 2021 8:00 AM - BizWire Pre-Open Stock Movers 02/01: (VIE) (THCB) (CDE) Higher; (QTNT) (NNOX) (GME) Lower (more...) February 1, 2021 9:30 AM - StreetInsider Gilead Sciences (GILD) to Increase Its Ownership In Arcus Biosciences (RCUS) to 19.5% February 1, 2021 8:05 AM - StreetInsider Gilead Sciences (GILD) and Gritstone (GRTS) Announce Pact Utilizing Gritstone's Vaccine Platform Technology for HIV Cure February 1, 2021 6:20 AM - StreetInsider Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure February 1, 2021 6:00 AM - BizWire Form 4 GILEAD SCIENCES INC For: Jan 28 Filed by: Horning Sandra January 29, 2021 5:47 PM - SEC Filing Form SC 13G/A GILEAD SCIENCES INC Filed by: BlackRock Inc. January 29, 2021 10:00 AM - SEC Filing Carvana (CVNA), Alphabet (GOOGL), Walmart (WMT) and RingCentral (RNG) Find Their Place in Jefferies' Franchise Pick List January 29, 2021 9:50 AM - StreetInsider Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: Pletcher Brett A January 28, 2021 8:09 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: Wilfong Diane E. January 28, 2021 8:07 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: Mercier Johanna January 28, 2021 8:05 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: Parsey Merdad January 28, 2021 7:58 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: O'Day Daniel Patrick January 28, 2021 7:52 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Jan 26 Filed by: Dickinson Andrew D January 28, 2021 7:45 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Jan 22 Filed by: Lofton Kevin E January 25, 2021 1:56 PM - SEC Filing Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021 January 21, 2021 4:01 PM - BizWire Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research January 19, 2021 8:00 AM - BizWire Morgan Stanley Upgrades Gilead Sciences (GILD) to Overweight for 2 Reasons January 19, 2021 12:55 AM - StreetInsider Gilead Sciences (GILD) Management Meeting Reveals 5 Takeaways and a Path to $75 - Jefferies January 14, 2021 8:43 AM - StreetInsider Gilead (GILD) and Vir Biotechnology (VIR) Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus January 12, 2021 8:05 AM - StreetInsider Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus January 12, 2021 8:00 AM - BizWire Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus January 12, 2021 8:00 AM - Globe NewsWire Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus January 12, 2021 8:00 AM - StreetInsider Gilead Sciences (GILD) PT Raised to $65 at BMO Capital January 12, 2021 6:27 AM - StreetInsider Gilead Sciences (GILD) Remdesivir Sales Will be Short-Lived - Raymond James January 11, 2021 10:57 AM - StreetInsider Pre-Open Stock Movers 01/11: (MESO) (LLY) (WBAI) Higher; (MARA) (RIOT) (MSTR) Lower (more...) January 11, 2021 9:23 AM - StreetInsider Gilead Sciences (GILD) Raises FY20 Guidance Due to Remdesivir Sales January 11, 2021 6:07 AM - StreetInsider Form 8-K GILEAD SCIENCES INC For: Jan 11 January 11, 2021 6:05 AM - SEC Filing Gilead Sciences Announces Updated 2020 Guidance January 11, 2021 6:00 AM - BizWire Form 8-K/A GILEAD SCIENCES INC For: Oct 23 January 6, 2021 5:26 PM - SEC Filing Gilead Sciences' (GILD) Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors January 6, 2021 8:10 AM - StreetInsider Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors January 6, 2021 8:00 AM - BizWire Form 4 GILEAD SCIENCES INC For: Dec 30 Filed by: Whitley Richard James January 4, 2021 1:25 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Dec 30 Filed by: Lofton Kevin E January 4, 2021 1:21 PM - SEC Filing Guggenheim Upgrades Gilead Sciences (GILD) to Buy January 4, 2021 6:26 AM - StreetInsider Gilead Sciences (GILD) Grinds Higher Into Close December 31, 2020 3:59 PM - StreetInsider Stocks with Implied Volatility Movement December 31, 2020 4:34 AM - StreetInsider Form 4 GILEAD SCIENCES INC For: Nov 23 Filed by: Lofton Kevin E December 29, 2020 3:09 PM - SEC Filing Stocks with Implied Volatility Movement December 28, 2020 4:29 AM - StreetInsider Stocks with Implied Volatility Movement December 24, 2020 4:18 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $72 at Citi December 22, 2020 5:37 AM - StreetInsider Stocks with Implied Volatility Movement December 22, 2020 4:50 AM - StreetInsider Gilead Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 December 21, 2020 4:01 PM - BizWire Gilead Sciences (GILD) PT Lowered to $62 at Truist Securities December 17, 2020 5:12 PM - StreetInsider Gilead Sciences (GILD) PT Lowered to $100 at Oppenheimer December 17, 2020 7:49 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $80 at Piper Sandler December 16, 2020 9:02 AM - StreetInsider UPDATE: Gilead Sciences (GILD) PT Lowered to $68 at BofA Securities December 16, 2020 6:39 AM - StreetInsider Gilead's (GILD) Kite Tecartus Granted Conditional Marketing Authorization for Treatment of R/R Mantle Cell Lymphoma in Europe December 16, 2020 6:14 AM - StreetInsider Gilead Sciences (GILD) PT Lowered to $65 at Credit Suisse December 16, 2020 4:40 AM - StreetInsider Gilead Sciences (GILD) IV flat as shares near eight-month high December 16, 2020 4:32 AM - StreetInsider Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe December 16, 2020 3:01 AM - BizWire Gilead Sciences (GILD), Galapagos NV (GLPG) Amend Development Agreement for Jyselec December 15, 2020 4:16 PM - StreetInsider Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib) December 15, 2020 4:15 PM - BizWire Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  Jyseleca®  (filgotinib)   December 15, 2020 4:15 PM - StreetInsider Gilead Sciences (GILD) KOL Call Takeaways on Trodelvy - RBC Capital December 15, 2020 6:07 AM - StreetInsider Redburn Reinstates Gilead Sciences (GILD) at Neutral December 14, 2020 4:44 AM - StreetInsider Gilead Sciences (GILD) Acquisition of MYR Makes Sense - Morgan Stanley December 11, 2020 6:42 AM - StreetInsider Gilead (GILD) Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy in Metastatic TNBC December 10, 2020 4:48 PM - StreetInsider Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer December 10, 2020 4:48 PM - BizWire Form 4 GILEAD SCIENCES INC For: Dec 08 Filed by: Bluestone Jeffrey December 10, 2020 4:11 PM - SEC Filing Form 3 GILEAD SCIENCES INC For: Dec 07 Filed by: Bluestone Jeffrey December 10, 2020 4:08 PM - SEC Filing Gilead Sciences (GILD) call put ratio 2.6 calls to 1 put into FDA panel votes on Pfizer’s (PFE) Covid vaccine December 10, 2020 10:02 AM - StreetInsider Intercept Pharma (ICPT) on Watch on Chatter December 10, 2020 9:49 AM - StreetInsider Gilead Sciences to Acquire MYR GmbH December 10, 2020 9:20 AM - PR NewsWire Gilead Sciences (GILD) to Acquire MYR GmbH in Deal Valued at Over 1.15 Billion Euro December 10, 2020 8:01 AM - StreetInsider Gilead Sciences to Acquire MYR GmbH December 10, 2020 8:00 AM - BizWire Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States December 9, 2020 11:00 AM - BizWire Form 8-K GILEAD SCIENCES INC For: Dec 07 December 8, 2020 4:14 PM - SEC Filing Gilead Sciences (GILD) Announces Jeffrey A. Bluestone to Board December 8, 2020 4:11 PM - StreetInsider Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors December 8, 2020 4:05 PM - BizWire Pre-Open Stock Movers 12/07: (KODK) (CKH) Higher; (RIDE) (XPEV) (JKS) Lower (more...) December 7, 2020 9:26 AM - StreetInsider Matinas BioPharma (MTNB) Announces Collaboration with NIAID to Evaluate Oral Formulations of Gilead's (GILD) Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology December 7, 2020 6:37 AM - StreetInsider Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma December 7, 2020 6:35 AM - StreetInsider Gilead's (GILD) Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients December 7, 2020 6:35 AM - StreetInsider Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platf December 7, 2020 6:35 AM - Globe NewsWire Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platf December 7, 2020 6:35 AM - StreetInsider Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma December 6, 2020 3:00 PM - BizWire Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients December 6, 2020 12:30 PM - BizWire Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study December 5, 2020 12:30 PM - BizWire New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma December 5, 2020 10:00 AM - BizWire New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial December 5, 2020 10:00 AM - BizWire Full Article List